UNITED BIOSOURCE ACQUIRES METAWORKS, INC
United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services.
Bethesda, MD – January 17, 2006 – United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services. The acquisition is part of the UBC strategy of building integrated capabilities to meet growing demand by the pharmaceutical, biotech, medical device and diagnostics sectors for evidence-based product development and commercialization services.
MetaWorks, Inc, provides an array of clinical data products and scientific consulting services to aid the development and commercialization of drugs, devices, diagnostics, and procedures. The company is a world leader in systematic literature reviews of clinical data and the application of complex statistical methods, such as meta-analysis. MetaWorks' database assets include MetaHub™,a proprietary warehouse of formatted, synthesized, and appraised clinical trial data. MetaWorks is a privately held company and currently serves more than 75 clients in the life sciences industry.
UBC delivers evidence-based services to enhance the medical and commercial potential of pharmaceuticals, biotechnology, medical devices and diagnostics. The company leverages a unique suite of scientific capabilities to demonstrate product effectiveness and safety, manage and minimize risk, document economic value, and secure appropriate third-party payment for prescription medicines and other medical technology.
"MetaWorks' scientific capabilities are on the forefront of decision-making in biopharmaceutical product development and commercialization," said UBC founder and CEO Ethan Leder. "Systematic literature reviews and meta-analyses help drug researchers identify precise scientific objectives before investing in costly clinical trials to test their hypotheses."
"UBC gives us the expanded reach, additional resources, and expertise we need to meet the growing demand for our analytic and consulting services and data products," said Shubh Sethi, MetaWorks President and CEO. Susan Ross, MD, MetaWorks' scientific co-founder, added, "By joining forces with UBC, we can take the pursuit of our mission – harnessing the power of data for health care – to a higher level than ever before".
The addition of MetaWorks is the latest in a series of acquisitions announced since UBC raised $153 million in equity capital from a syndicate of leading private equity firms. MetaWorks will join UBC's
Health Care Analytics Group
, formerly MEDTAP International, the company's team of world-recognized research scientists. The MetaWorks management team will assume leadership roles within UBC's
Health Care Analytics Group
. MetaWorks' operations will remain headquartered in Medford, MA.
About UBC
United BioSource Corporation (UBC) delivers evidence-based solutions to enhance the medical and commercial potential of pharmaceuticals, biotechnology, medical devices, and diagnostics. UBC is based in Bethesda, Maryland. For more information, visit www.unitedbiosource.com or call 240-644-0420.
About Metworks
MetaWorks® Inc. is an evidence-based consulting company focused on product development and commercialization within the biopharmaceutical, device, and health care industries. MetaWorks Inc is based in Medford, Massachusetts. For more information, visit
www.metaworksinc.com
.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
